stockrowResMed Inc.
RMD Healthcare Medical Instruments & Supplies
ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025.
- Revenue
- +5.93%
- EPS
- +23.1%
- Free cash flow
- −9.79%
- Total debt
- −38.9%
Quarter to September 2026, against a year earlier
Follow RMD
Alert me
ResMed Inc. (RMD) Revenue growth
ResMed Inc.'s revenue growth over the twelve months to 30 September 2026 was 9.04%, down 0.8 percentage points from fiscal 2026 (9.85%). Over the past ten years it has ranged from 7.97% (fiscal 2015) to 18.0% (fiscal 2023); the current reading is higher than 42% of that period. That is in line with the Medical Instruments & Supplies industry median of 8.97% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2026 | 9.85% | 0.01 |
| FY2025 | 9.84% | (1.11) |
| FY2024 | 11.0% | (7.07) |
| FY2023 | 18.0% | 6.09 |
| FY2022 | 11.9% | 3.82 |
| FY2021 | 8.11% | (5.33) |
| FY2020 | 13.4% | 2.06 |
| FY2019 | 11.4% | (1.85) |
| FY2018 | 13.2% | 0.83 |
| FY2017 | 12.4% | 2.88 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 5.93% | (2.65) |
| Jun 2026 | 8.58% | (2.23) |
| Mar 2026 | 10.8% | (0.17) |
| Dec 2025 | 11.0% | 1.91 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| WST West Pharmaceutical Services, Inc. compare | 12.6% |
| RMD ResMed Inc. | 9.04% |
| ALC Alcon compare | 8.34% |
| BAX Baxter International Inc. compare | 5.33% |
| COO The Cooper Companies, Inc. compare | 4.73% |
| ALGN Align Technology, Inc. compare | 4.42% |
| BDX Becton, Dickinson and Company compare | −2.55% |
| SOLV Solventum Corporation compare | −2.84% |
| MDLN Medline Inc. compare | — |
| Medical Instruments & Supplies industry median | 8.97% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on RMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement